Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.40.
A number of research firms have recently issued reports on MIST. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company lowered their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Tuesday, July 14th.
Read Our Latest Report on MIST
Institutional Inflows and Outflows
Milestone Pharmaceuticals Price Performance
Milestone Pharmaceuticals stock opened at $1.18 on Thursday. The stock has a market capitalization of $146.91 million, a price-to-earnings ratio of -1.71 and a beta of 0.98. Milestone Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $3.06. The stock’s 50 day moving average price is $1.20 and its two-hundred day moving average price is $1.47. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. On average, equities analysts predict that Milestone Pharmaceuticals will post -0.84 earnings per share for the current year.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.
Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.
Read More
- Five stocks we like better than Milestone Pharmaceuticals
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
